Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Bevacizumab
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Colorectal Cancer
Fabricant:
Hoffmann-La Roche Limited
Brand Name:
Avastin (with capecitabine)
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0055-000
Strength:
25 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy
Review Status:
Complete
Date NOC Issued:
Sponsor:
Cancer Care Ontario Gastrointestinal Disease Site Group
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016